AOD-9604 dosage: almost all the evidence is in animals, not people

AOD-9604 is sold with dosage charts that read like they came out of a finished human trial: a set number of micrograms, injected on a schedule, sometimes tapered over weeks. They didn’t come from one. The compound reached Phase IIa human testing for obesity by February 2002 under its developer, a company called Metabolic^[1], and from there the citable trail goes cold.

No peer-reviewed report of a larger human efficacy trial, no published human dosing study, and no dedicated human safety paper turned up anywhere in PubMed, Europe PMC, or Crossref. What exists instead is a small stack of rat, mouse, and cell studies, and a rat study is not a dosing instruction for a person.

What AOD-9604 is, and how far it got

AOD-9604 is a synthetic fragment of human growth hormone. In the literature it’s described as an analogue of hGH’s lipolytic domain, the piece of the hormone tied to fat breakdown rather than to growth^[2]. The idea, going back decades, was to keep the fat-mobilizing effect of growth hormone while cutting away the parts that make it grow tissue and disturb blood sugar.

By 2004, a drug-development report placed AOD-9604 in Phase IIa trials for obesity, sponsored by Metabolic^[1]. That report doesn’t give a participant count, a design, or an outcome. It says the trials were underway, and nothing more specific survives in the indexed literature. Whatever happened in a later, larger trial, and marketing copy for AOD-9604 often implies one, was never published anywhere a reader can check it.

What we could not verify: any trial result, any human dose, and any human safety record for AOD-9604. That gap is the whole story here.

The animal data behind the fat-loss claim

The strongest data on AOD-9604 comes from obese Zucker rats. Daily oral AOD-9604 at 500 micrograms per kilogram of body weight, given for 19 days, cut body-weight gain from 35.6 grams in untreated controls to 15.8 grams in treated animals, and increased lipolytic activity in their fat tissue^[2]. Unlike chronic treatment with intact growth hormone in the same model, AOD-9604 didn’t reduce insulin sensitivity.

56% less body-weight gain than controls in obese rats given oral AOD-9604 for 19 days PMID 11146367

A separate study in obese and lean mice tested the mechanism directly. Researchers gave hGH, AOD-9604, or saline for 14 days, then used growth-hormone-receptor-transfected cells to check whether AOD-9604 could bind and activate that receptor the way hGH does, and it could not. AOD-9604 didn’t compete for the growth hormone receptor and didn’t trigger cell proliferation through it, while hGH did both^[3]. That’s the mechanistic basis usually cited for why AOD-9604 shouldn’t raise IGF-1 the way full growth hormone does, though this particular study didn’t measure IGF-1 itself.

Tesamorelin takes the opposite engineering route. Instead of clipping a fragment off growth hormone, it’s an analogue of growth-hormone-releasing hormone, the signal that tells the pituitary to make more GH in the body’s own pulsatile pattern^[4]. Two different peptides, two different ways of trying to reach the same fat-loss goal, and only one of them has a published human trial behind it.

The dosing gap: what’s published, and what’s just on a forum

Here is the practical problem for anyone searching “AOD-9604 dosage.” No published human dosing study exists in the indexed literature. The only dose we could verify anywhere is the rat protocol above, and a rat dose does not translate into a human one without the pharmacokinetic work that was never published.

The dosing charts in circulation for AOD-9604 don't trace back to a published human trial.

What that means in practice:

• Retail and forum dosing charts for subcutaneous AOD-9604 aren’t drawn from the rat oral-dose study, and they haven’t been tested in any controlled human study of their own.
• No regulator has approved a dose of AOD-9604 for any indication, so there’s no clinically established number to defer to.
• Long-term safety data don’t exist because no published human trial ran long enough, or at all, to generate them.
• Product sold under the AOD-9604 name outside a trial setting isn’t subject to the manufacturing and purity oversight that an approved pharmaceutical would receive.

That last point matters more than it sounds. A dose is only as meaningful as the thing being dosed, and nothing in the published record confirms what’s in a vial bought outside a clinical trial.

A second use case, tested only in rabbits

AOD-9604 has also been tested for cartilage repair, a separate use case from fat loss. In a rabbit model of collagenase-induced knee osteoarthritis, weekly intra-articular injections of 0.25 mg AOD-9604, with or without 6 mg of hyaluronic acid, produced better cartilage-repair scores and shorter lameness than saline over four to seven weeks^[5]. The combination of AOD-9604 with hyaluronic acid outperformed either one alone.

That’s a real finding, and it’s an animal finding. Nothing in the citable record extends it to a human osteoarthritis trial. A rabbit knee is not a human knee, and a compound that helps one is not thereby proven to help the other.

Where that leaves AOD-9604 against its competition

AOD-9604: what's verified in the citable literature

Based on the citable literature retrieved for this article.

Tesamorelin, the growth-hormone-releasing-hormone analogue mentioned above, is FDA approved for reducing excess abdominal fat in patients with HIV-associated lipodystrophy^[4]. That’s a regulatory finish line AOD-9604 has never reached for any indication, obesity or otherwise. GLP-1 receptor agonists have an even larger base of randomized human trials behind their weight-loss effects, which only sharpens the contrast: better-studied options for fat loss already exist, and AOD-9604 isn’t one of them. For a fuller comparison of tesamorelin’s evidence base, see our separate deep-dive.

None of this is unique to the dosing question. The companion piece on AOD-9604’s benefits claims runs into the identical wall: a Phase IIa mention, and then silence where the efficacy data should be.

What would change this

A published human trial, efficacy or safety, would change the picture immediately. So would a human osteoarthritis trial replicating the rabbit cartilage findings. Neither exists yet, and no actively recruiting AOD-9604 trial for obesity is easy to find on the major registries years after that Phase IIa mention.

Bottom line: AOD-9604 has real animal pharmacology behind it: it mobilizes fat in rats without the insulin problems of intact growth hormone, and it doesn’t touch the growth hormone receptor in a cell assay. What it doesn’t have is a published human trial telling anyone what dose, if any, does the same thing in a person. Until that changes, any dosage number attached to AOD-9604 is someone’s guess dressed up as a finding.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.